We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FULVESTRANT EVER PHARMA (Interpharma Pty Ltd)
Product name
FULVESTRANT EVER PHARMA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
132 (255 working days)
Active ingredients
fulvestrant
Registration type
New generic medicine
Indication
FULVESTRANT EVER PHARMA (solution for injection) is indicated for the treatment of postmenopausal women with:
- hormone-receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.
- HR positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.